Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: The role of D2 receptor activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 1, 2010, Pages 207-212

  Hadlock, Gregory C ^a   Chu, Pei Wen ^b   Walters, Elliot T ^a   Hanson, Glen R ^a,b   Fleckenstein, Annette E ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE; VESICULAR MONOAMINE TRANSPORTER 2; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE UPTAKE INHIBITOR; ETICLOPRIDE; SALICYLAMIDE DERIVATIVE; SLC18A2 PROTEIN, RAT; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; DRUG ABUSE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; AGONISTS; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; METABOLISM; MOLECULAR WEIGHT; PHYSIOLOGY; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; ASTROCYTES; BLOTTING, WESTERN; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; GLIAL FIBRILLARY ACIDIC PROTEIN; MALE; METHAMPHETAMINE; MOLECULAR WEIGHT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 77957227921     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166660     Document Type: Article

References (35)

1. Baucum AJ 2nd, Rau KS, Riddle EL, Hanson GR, and Fleckenstein AE (2004) Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J Neurosci 24:3436-3443.
2. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, Ali SF, and Holson RR (1992) The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260:817-824.
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
4. Broening HW, Morford LL, and Vorhees CV (2005) Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 56:84-93.
5. Broening HW, Pu C, and Vorhees CV (1997) Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse 27:153-160.
6. Brown JM and Yamamoto BK (2003) Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther 99:45-53.
7. Brown JM, Hanson GR, and Fleckenstein AE (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74:2221-2223.
8. Cass WA (1997) Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. J Pharmacol Exp Ther 280:105-113.
9. Chu PW, Seferian KS, Birdsall E, Truong JG, Riordan JA, Metcalf CS, Hanson GR, and Fleckenstein AE (2008) Differential regional effects of methamphetamine on dopamine transport. Eur J Pharmacol 590:105-110.
10. Cubells JF, Rayport S, Rajendran G, and Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 14:2260-2271.
11. Eisch AJ, Gaffney M, Weihmuller FB, O'Dell SJ, and Marshall JF (1992) Striatal subregions are differentially vulnerable to the neurotoxic effects of methamphetamine. Brain Res 598:321-326.
12. Eng LF, Ghirnikar RS, and Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 25:1439-1451.
13. Eyerman DJ and Yamamoto BK (2005) Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J Pharmacol Exp Ther 312:160-169.
14. Eyerman DJ and Yamamoto BK (2007) A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J Neurochem 103:1219-1227.
15. Fleckenstein AE, Volz TJ, and Hanson GR (2009) Psychostimulant-induced alterations in vesicular monoamine transporter-2 function: neurotoxic and therapeutic implications. Neuropharmacology 56:133-138.
16. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, and Caron MG (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19:2424-2431.
17. Guillot TS, Richardson JR, Wang MZ, Li YJ, Taylor TN, Ciliax BJ, Zachrisson O, Mercer A, and Miller GW (2008a) PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides 42:423-434.
18. Guillot TS, Shepherd KR, Richardson JR, Wang MZ, Li Y, Emson PC, and Miller GW (2008b) Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis. J Neurochem 106:2205-2217.
19. Hadlock GC, Baucum AJ 2nd, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, and Fleckenstein AE (2009) Mechanisms underlying methamphetamine-induced dopamine transporter complex formation. J Pharmacol Exp Ther 329:169-174.
20. Haughey HM, Fleckenstein AE, and Hanson GR (1999) Differential regional effects of methamphetamine on the activities of tryptophan and tyrosine hydroxylase. J Neurochem 72:661-668.
21. Krasnova IN and Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60:379-407.
22. LaVoie MJ, Card JP, and Hastings TG (2004) Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 187:47-57.
23. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, and Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinon users: evidence from positron emission tomography studies with [11C] WIN-35,428. J Neurosci 18:8417-8422.
24. O'Callaghan JP and Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
25. Quinton MS and Yamamoto BK (2006) Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 8:E337-E347.
26. Riddle EL, Topham MK, Haycock JW, Hanson GR, and Fleckenstein AE (2002) Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 449:71-74.
27. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, and Gibb JW (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233:539-544.
28. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, and Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214.
29. Thomas DM, Francescutti-Verbeem DM, and Kuhn DM (2008) The newly synthesized pool of dopamine determines the severity of methamphetamine-induced neurotoxicity. J Neurochem 105:605-616.
30. Thomas DM, Francescutti-Verbeem DM, and Kuhn DM (2009) Increases in cytoplasmic dopamine compromise the normal resistance of the nucleus accumbens to methamphetamine neurotoxicity. J Neurochem 109:1745-1755.
31. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, and Kuhn DM (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 311:1-7.
32. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382.
33. Wagner GC, Lucot JB, Schuster CR, and Seiden LS (1983) α-Methyltyrosine attenuates and reserpine increases methamphetamine induced neuronal changes. Brain Res 270:285-288.
34. Whitney NP, Eidem TM, Peng H, Huang Y, and Zheng JC (2009) Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem 108:1343-1359.
35. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, and Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703.